Correction to: Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer (npj Breast Cancer, (2022), 8, 1, (98), 10.1038/s41523-022-00467-1)

  1. Rugo, H.S.
  2. Tolaney, S.M.
  3. Loirat, D.
  4. Punie, K.
  5. Bardia, A.
  6. Hurvitz, S.A.
  7. O’Shaughnessy, J.
  8. Cortés, J.
  9. Diéras, V.
  10. Carey, L.A.
  11. Gianni, L.
  12. Piccart, M.J.
  13. Loibl, S.
  14. Goldenberg, D.M.
  15. Hong, Q.
  16. Olivo, M.
  17. Itri, L.M.
  18. Kalinsky, K.
Aldizkaria:
npj Breast Cancer

ISSN: 2374-4677

Argitalpen urtea: 2024

Alea: 10

Zenbakia: 1

Mota: Hutsen zuzenketa

DOI: 10.1038/S41523-024-00650-6 GOOGLE SCHOLAR lock_openSarbide irekia editor
Datuen iturria: Scopus